171 related articles for article (PubMed ID: 17185368)
1. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H
Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
3. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
4. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
[TBL] [Abstract][Full Text] [Related]
6. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
[TBL] [Abstract][Full Text] [Related]
7. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
J Urol; 2003 Oct; 170(4 Pt 1):1169-74. PubMed ID: 14501718
[TBL] [Abstract][Full Text] [Related]
8. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
11. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
12. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Partin AW; Catalona WJ; Finlay JA; Darte C; Tindall DJ; Young CY; Klee GG; Chan DW; Rittenhouse HG; Wolfert RL; Woodrum DL
Urology; 1999 Nov; 54(5):839-45. PubMed ID: 10565744
[TBL] [Abstract][Full Text] [Related]
13. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
14. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
15. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Martin BJ; Finlay JA; Sterling K; Ward M; Lifsey D; Mercante D; Jainto JM; Martin L; Rayford W
Prostate Cancer Prostatic Dis; 2004; 7(2):132-7. PubMed ID: 15007379
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
[TBL] [Abstract][Full Text] [Related]
17. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
[TBL] [Abstract][Full Text] [Related]
18. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Vickers AJ; Ulmert D; Serio AM; Björk T; Scardino PT; Eastham JA; Berglund G; Lilja H
Int J Cancer; 2007 Nov; 121(10):2212-7. PubMed ID: 17657743
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
